---
layout: use-case-detail
title: "Evaluation — Autonomous Adverse Event Report Processing in Pharmacovigilance"
uc_id: "UC-500"
uc_title: "Autonomous Adverse Event Report Processing in Pharmacovigilance"
detail_type: "evaluation"
detail_title: "Evaluation"
category: "Industry-Specific"
category_icon: "briefcase"
industry: "Pharmaceutical / Life Sciences"
complexity: "High"
status: "detailed"
slug: "UC-500-pharma-adverse-event-processing"
permalink: /use-cases/UC-500-pharma-adverse-event-processing/evaluation/
---

## Decision Summary

The business case for AI-assisted ICSR processing is strong. Multiple production deployments (ArisGlobal NavaX at 1M+ cases, IQVIA Vigilance Detect operational, Tech Mahindra PV Agentic LLM deployed) demonstrate that the technology works at scale. Published accuracy exceeds 95% for field-level extraction in production and F1 scores of 0.72–0.74 in early benchmarks have improved substantially with LLM-era models. The economics hold if a mid-size pharma company processes at least 5,000 cases/year — below that threshold, the integration cost into legacy safety databases may not justify the investment within two years.

## Published Evidence

| Deployment / Source | Published Metric | What It Shows |
|---------------------|------------------|---------------|
| ArisGlobal NavaX (2026, 6 top-25 pharma companies) | >95% data accuracy, >30% efficiency gain, 1M+ cases processed | Production-grade accuracy is achievable at scale with current-generation AI |
| Pfizer AI Center of Excellence pilot (2019, PMC) | F1 scores 0.52–0.74 for ICSR field extraction; 81% case validity classification | Early ML approaches demonstrated feasibility; LLM-era systems substantially exceed these baselines |
| Tech Mahindra PV Agentic LLM (2025, with NVIDIA) | 60% manual effort reduction, 45% case prioritization improvement, 20% signal detection improvement | Agentic architecture delivers material throughput gains across the full PV lifecycle |
| IQVIA Vigilance Detect (2024–2025) | Up to 80% fewer false positives in AE detection; target of 50% cost reduction with >99% quality | GenAI dramatically reduces noise in intake processing; full autonomous processing still maturing |
| French ANSM regulatory deployment (2021) | AUC ~0.97 for ADR detection from patient reports | National regulator validated AI for production pharmacovigilance triage |

## Assumptions And Scenario Model

| Assumption | Value | Basis |
|------------|-------|-------|
| Annual case volume (mid-size pharma) | 10,000–50,000 ICSRs/year | ProPharma processes 2,000+/month for clients; large pharma handles tens of thousands internally |
| Current cost per case (fully loaded) | $80–$180 per routine ICSR | 2–4 hours at $38–$44/hour median specialist rate, plus overhead (QC, systems, management) |
| Autonomous processing rate (non-serious cases) | 40–60% of total volume | Industry consensus for non-serious spontaneous cases meeting confidence thresholds |
| Per-product PV annual cost | ~$686K/year | Published industry benchmark for safety data management per marketed product |
| AI processing cost per case | $2–$8 per case (API + compute) | Based on multi-step LLM calls (~10K tokens input, ~2K output per step, 5–7 steps) at current API pricing |

## Expected Economics

| Factor | Value | Note |
|--------|-------|------|
| **Current cost** | $686K/year per product (data management); $80–$180 per case (processing labor) | Published industry benchmark |
| **Expected steady-state cost** | 35–50% of current processing labor cost | Estimated: autonomous cases eliminate labor; human-reviewed cases retain AI pre-population savings of ~40% |
| **Expected benefit** | $240K–$450K annual savings per product (labor) + reduced late-submission risk | Estimated based on 50% FTE reduction on a $686K baseline, adjusted for cases still requiring human review |
| **Implementation cost** | $800K–$1.5M (integration, validation, rollout) | Estimated: safety DB integration is the major cost driver; GxP validation adds 30–40% vs. non-regulated AI deployments |
| **Payback view** | 12–24 months for a company with >5 products | Estimated: scales favorably — integration cost is largely fixed, per-product savings are recurring |

## Quality, Risk, And Failure Modes

| Area | Strength / Risk | Control Or Mitigation |
|------|-----------------|-----------------------|
| Field extraction accuracy | Strength: >95% demonstrated in production (ArisGlobal); strong structured output from current LLMs | Confidence threshold gates autonomous processing; validation engine catches schema violations |
| Seriousness misclassification | Risk: a non-serious classification on a serious case could cause a missed 7-day deadline | Deterministic rule re-check after AI classification; err toward serious when ambiguous; any death/hospitalization keyword forces human review |
| MedDRA coding drift | Risk: model could favor common terms over precise low-frequency codes | RAG against versioned dictionary (not fine-tuned model); audit sampling; biannual re-indexing on MedDRA release |
| Regulatory inspection readiness | Strength: full audit trail of AI decisions satisfies GxP requirements | Every agent output logged with timestamp, confidence, and source traceability; human overrides captured with reason |
| Narrative hallucination | Risk: LLM generates plausible but unsupported clinical detail | Grounding constraint in prompt; post-generation assertion check against extracted data; zero-tolerance gate in evaluation harness |
| Vendor lock-in (safety DB) | Risk: tight coupling to Oracle Argus API limits flexibility | E2B(R3) as intermediate format provides abstraction; adapter pattern isolates DB-specific logic |

## Rollout KPI Set

| KPI | Why It Matters | Pilot Gate |
|-----|----------------|------------|
| Field-level extraction accuracy (F1) | Core quality metric; directly affects case data correctness | > 0.90 overall; > 0.95 for suspect drug and seriousness fields |
| Autonomous processing rate | Measures labor savings realization | > 40% of non-serious spontaneous cases processed without human intervention |
| Seriousness classification sensitivity | Safety-critical: must not miss serious cases | > 0.98 (no more than 2% of serious cases incorrectly classified as non-serious) |
| End-to-end processing time (P95) | Proves throughput improvement over 2–4 hour baseline | < 30 minutes for autonomously processed cases |
| Regulatory submission acceptance rate | Validates E2B(R3) output quality | > 99% acceptance at gateway |
| Human escalation rate | Too high means AI is not autonomous enough; too low means risk of missed edge cases | 30–50% of all cases (target equilibrium for mixed portfolio) |
| Late submission rate | Regulatory compliance: 7-day and 15-day deadlines | 0% late submissions (same or better than pre-AI baseline) |

## Open Questions

- How will regulators (FDA, EMA) treat AI-generated ICSRs during GxP inspections? The FDA's January 2025 draft guidance on AI in drug development acknowledges AI use but does not yet provide pharmacovigilance-specific validation requirements.
- What is the minimum volume threshold below which the integration cost into Oracle Argus (or equivalent) does not pay back within 24 months? Preliminary estimate is ~5,000 cases/year but this depends heavily on existing system customization.
- Can causality assessment (currently reserved for humans) be partially automated for well-characterized drug-event pairs with strong historical precedent? This would further reduce specialist workload but introduces higher regulatory risk.
- How should the system handle multi-language intake at scale? ArisGlobal's NavaX Translation (launching July 2026) suggests the industry is moving toward integrated AI translation, but validation of translated medical content in a GxP context remains an open challenge.
